J. Goldman & CO LP Harmony Biosciences Holdings, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
A detailed history of J. Goldman & CO LP transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 27,600 shares of HRMY stock, worth $939,228. This represents 0.02% of its overall portfolio holdings.
Number of Shares
27,600Holding current value
$939,228% of portfolio
0.02%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding HRMY
# of Institutions
317Shares Held
43.9MCall Options Held
1.05MPut Options Held
310K-
Black Rock Inc. New York, NY5.84MShares$199 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.1MShares$173 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.69MShares$57.6 Million0.01% of portfolio
-
American Century Companies Inc Kansas City, MO1.67MShares$56.8 Million0.02% of portfolio
-
State Street Corp Boston, MA1.65MShares$56.3 Million0.0% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.01B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...